K.N. Chi

2.4k total citations
76 papers, 1.6k citations indexed

About

K.N. Chi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, K.N. Chi has authored 76 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in K.N. Chi's work include Prostate Cancer Treatment and Research (53 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (10 papers). K.N. Chi is often cited by papers focused on Prostate Cancer Treatment and Research (53 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (10 papers). K.N. Chi collaborates with scholars based in Canada, United States and United Kingdom. K.N. Chi's co-authors include Scott North, Susan Ellard, Andrew J. Armstrong, Krista Noonan, Rhonda L. Bitting, Eric Winquist, Malcolm J. Moore, D. Scott Ernst, Fred Saad and Sébastien J. Hotte and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

K.N. Chi

69 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K.N. Chi Canada	17	1.2k	703	462	405	397	76	1.6k
Rosa Nadal United States	18	1.4k 1.2×	572 0.8×	520 1.1×	523 1.3×	472 1.2×	48	1.9k
Martin Boegemann Germany	19	1.2k 1.0×	430 0.6×	630 1.4×	388 1.0×	228 0.6×	90	1.4k
Pasquale Rescigno Italy	22	773 0.7×	317 0.5×	229 0.5×	397 1.0×	381 1.0×	82	1.3k
Tony Elliott United Kingdom	22	736 0.6×	503 0.7×	252 0.5×	213 0.5×	326 0.8×	58	1.6k
Fabian Zohren United States	14	690 0.6×	288 0.4×	197 0.4×	230 0.6×	331 0.8×	44	1.1k
Alejo Rodríguez‐Vida Spain	18	686 0.6×	484 0.7×	223 0.5×	263 0.6×	359 0.9×	95	1.1k
Kevin Beja Canada	16	1.4k 1.1×	545 0.8×	157 0.3×	1.0k 2.5×	552 1.4×	25	1.7k
Mario Eisenberger United States	14	981 0.8×	398 0.6×	366 0.8×	247 0.6×	234 0.6×	32	1.5k
Haruhiro Yukiue Japan	29	1.1k 0.9×	812 1.2×	134 0.3×	352 0.9×	839 2.1×	71	2.0k
Andrea Zivi United Kingdom	15	643 0.5×	185 0.3×	284 0.6×	283 0.7×	346 0.9×	46	950

Countries citing papers authored by K.N. Chi

Since Specialization

Citations

This map shows the geographic impact of K.N. Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.N. Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.N. Chi more than expected).

Fields of papers citing papers by K.N. Chi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.N. Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.N. Chi. The network helps show where K.N. Chi may publish in the future.

Co-authorship network of co-authors of K.N. Chi

This figure shows the co-authorship network connecting the top 25 collaborators of K.N. Chi. A scholar is included among the top collaborators of K.N. Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.N. Chi. K.N. Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, K.N. Chi, Neal D. Shore, et al.. (2025). Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 36(11). 1319–1330. 4 indexed citations

Merseburger, Axel S., Neeraj Agarwal, Anders Bjartell, et al.. (2023). 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT). Annals of Oncology. 34. S965–S966. 2 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

Horvath, Lisa G., Ian D. Davis, Andrew Martin, et al.. (2023). 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Annals of Oncology. 34. S968–S969. 2 indexed citations

Attard, G., Shahneen Sandhu, Dana E. Rathkopf, et al.. (2023). 1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial. Annals of Oncology. 34. S976–S977. 2 indexed citations

Chowdhury, S., Anders Bjartell, Neeraj Agarwal, et al.. (2023). Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Annals of Oncology. 34(5). 477–485. 59 indexed citations

Smith, Matthew R., Shahneen Sandhu, Daniel J. George, et al.. (2021). 582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD). Annals of Oncology. 32. S632–S633. 1 indexed citations

Fizazi, Karim, Ken Herrmann, Bernd J. Krause, et al.. (2021). 576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 32. S627–S628. 3 indexed citations

Halabi, Susan, Catherine M. Tangen, Mark Rosenthal, et al.. (2020). Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Annals of Oncology. 31(7). 930–941. 13 indexed citations

10.

Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). 610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology. 31. S508–S508. 7 indexed citations

11.

Bernstein, Vanessa, Susan Ellard, Susan Dent, et al.. (2017). A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167(2). 485–493. 79 indexed citations

12.

Bono, Johann S. de, Sergio Bracarda, K.N. Chi, et al.. (2017). Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v290–v290. 3 indexed citations

13.

Petrylak, Daniel P., K.N. Chi, Alexandra Drakaki, et al.. (2017). RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology. 28. v621–v621. 4 indexed citations

14.

Vaishampayan, Ulka N., Bruce Montgomery, Michael S. Gordon, et al.. (2017). EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy. Annals of Oncology. 28. v274–v274. 2 indexed citations

15.

Nappi, Lucia, Ladan Fazli, K.N. Chi, et al.. (2017). Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371. Annals of Oncology. 28. v325–v325. 1 indexed citations

16.

Chi, K.N., Andrew Protheroe, A. Rodrı́guez-Antolı́n, et al.. (2017). Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO). Annals of Oncology. 28. v269–v269. 6 indexed citations

17.

Chi, K.N., Evan Y. Yu, Cindy Jacobs, et al.. (2016). A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Annals of Oncology. 27(6). 1116–1122. 77 indexed citations

18.

Fizazi, Karim, Sébastien J. Hotte, Fred Saad, et al.. (2016). genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. vi564–vi564. 3 indexed citations

19.

Oechsle, Karin, Friedemann Honecker, Tina Cheng, et al.. (2011). Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Annals of Oncology. 22(12). 2654–2660. 72 indexed citations

20.

Michels, Jorg, Susan Ellard, Lyly Le, et al.. (2009). A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Annals of Oncology. 21(2). 305–311. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact